Apremilast Treatment for Pruritus and Quality of Life in Scalp Psoriasis

NCT ID: NCT03553433

Last Updated: 2018-06-12

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE4
• Total Enrollment: 90 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2018-06-30
• Study Completion Date: 2020-06-30

Brief Summary

A phase 4 multicenter, randomized, placebo-controlled Study evaluating the Effect of Apremilast on Pruritus and Quality of Life of Patients with moderate-to-severe Scalp Psoriasis

Detailed Description

The scalp is the most frequently affected body region in psoriasis. Scalp Psoriasis can impair the quality of life greatly due to pruritus. This is however not usually investigated as a primary outcome of treatments.

This study will investigate the effects of apremilast on the pruritus and quality of life and other patient reported outcomes in patients with scalp psoriasis.

Conditions

Psoriasis of Scalp; Psoriasis Vulgaris

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

Verum

Apremilast 30mg bd

Group Type: EXPERIMENTAL

Apremilast 30mg

Intervention Type: DRUG

Anti-psoriatic drug

Placebo Oral Tablet

Excipiens

Group Type: PLACEBO_COMPARATOR

Placebo Oral Tablet

Intervention Type: DRUG

Indistinguishable tablets not containing apremilast, Placebo Oral Tablet

Interventions

Apremilast 30mg

Anti-psoriatic drug

Intervention Type: DRUG

Placebo Oral Tablet

Indistinguishable tablets not containing apremilast, Placebo Oral Tablet

Intervention Type: DRUG

Other Intervention Names

Otezla; Placebo

Eligibility Criteria

Inclusion Criteria

1. Adult (>18yrs);

2. Signed informed consent

3. Clinical diagnosis of chronic plaque psoriasis for at least 3 months as determined by the subject's medical history and confirmation of diagnosis through physical examination by the Investigator;

4. Psoriatic lesions with DLQI >10 and involvement of >20% of the scalp and pruritus with a VAS score of > 50 (0-100);

5. Candidate for systemic therapy;

6. Females who are of child-bearing potential should be practicing birth control throughout the study and for 70 days after the last dose of study drug;

7. Subject is judged to be in good health as determined by the Investigator based upon the results of medical history, laboratory profile and physical examination.

8. Creatinine < 80 umol/l at Inclusion

Exclusion Criteria

1. Erythrodermic Ps, medication-induced or medication-exacerbated Ps or new onset guttate Ps or other skin conditions at the time of the screening visit (e.g. eczema) that would interfere with evaluations of the effect of the investigational product on Ps;

2. Use of any anti-psoriatic therapy last administered less than 4 weeks of start of study drug such as

1. Three months or 5 PK half-lives, whichever is longer, for biologics tumor necrosis factor (TNF) antagonists, interleukin (IL) 12/23/17 inhibitors or other biologic drugs

2. 4 weeks for immunosuppressive / -modulating drugs including cyclosporine A, methotrexate, azathioprine, mycophenolate mofetil, fumaric acid esters, retinoids, JAK inhibitors, corticosteroids, any other experimental drug, etc.

3. Topical medications (eg. Corticosteroids) except coal tar shampoo, and/or salicylic acid scalp preparations on scalp lesions.

4. 4 weeks for phototherapy (ie, UVB, PUVA).

3. Infection(s) requiring treatment with intravenous (IV) anti-infectives within 30 days prior to the Baseline visit or oral anti-infectives within 14 days prior to the Baseline visit;

4. Positive serology for hepatitis B, hepatitis C, HIV indicating acute or chronic infection;

5. Chronic recurring bacterial infections or active TB;

6. Positive pregnancy test at Screening or at the Baseline visit;

7. Female subjects who are pregnant or breast-feeding or considering becoming pregnant during the study;

8. History of clinically significant alcohol or drug abuse in the last 12 months;

9. Known hypersensitivity to the excipients of Otezla® as stated in the label;

10. Subject is considered by the Investigator, for any reason, to be an unsuitable candidate for the study.

11. Prior history of suicide attempt at any time in the subject's life time prior to signing the informed consent and randomization, or major psychiatric illness requiring hospitalization within the last 3 years prior to signing the informed consent.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

University of Zurich

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Alexander Navarini, MD PhD

Role: PRINCIPAL_INVESTIGATOR

University of Zurich

Locations

KSSG

Sankt Gallen, Canton of St. Gallen, Switzerland

Inselspital

Bern, , Switzerland

CHUV

Lausanne, , Switzerland

Department of Dermatology, University Hospital Zurich

Zurich, , Switzerland

Countries

Switzerland

Central Contacts

Alexander Navarini, MD PhD

Role: CONTACT

alexander.navarini@usz.ch

0041442551111

Karolina Papageorgiou, MD

Role: CONTACT

karolina.papageorgiou@usz.ch

0041442551111

Facility Contacts

Antonio Cozzio, MD PhD

Role: primary

antonio.cozzio@kssg.ch

+41 71 494 20 30

Nikhil Yawalkar, MD

Role: primary

nikhil.yawalkar@insel.ch

+41 (31) 632 22 88

Curdin Conrad, MD

Role: primary

curdin.conrad@chuv.ch

+41 21 314 0400

Other Identifiers

DER-USZ-AAN-021

Identifier Type: -

Identifier Source: org_study_id